Afficher la notice abrégée

hal.structure.identifierBioingénierie tissulaire [BIOTIS]
dc.contributor.authorCOMBE, Christian
hal.structure.identifierFriedrich-Alexander Universität Erlangen-Nürnberg = University of Erlangen-Nuremberg [FAU]
dc.contributor.authorMANN, Johannes
hal.structure.identifierGuy's and St Thomas' NHS Foundation Hospital [Londres, Royaume-Uni]
dc.contributor.authorGOLDSMITH, David
hal.structure.identifierDaVita Clinical Research [Düsseldorf, Allemagne]
dc.contributor.authorDELLANNA, Frank
hal.structure.identifierUniversité de Grenoble
dc.contributor.authorZAOUI, Philippe
dc.contributor.authorLONDON, Gérard
hal.structure.identifierMatrix45 [Tucson, Arizona]
hal.structure.identifierDepartment of Public Health [Basel, Suisse]
dc.contributor.authorDENHAERYNCK, Kris
hal.structure.identifierHexal AG [Holzkirchen, Allemagne]
dc.contributor.authorKRENDYUKOV, Andriy
hal.structure.identifierMatrix45 [Tucson, Arizona]
hal.structure.identifierCollege of Pharmacy and College of Medicine [Tucson, Arizona]
dc.contributor.authorABRAHAM, Ivo
hal.structure.identifierMatrix45 [Tucson, Arizona]
dc.contributor.authorMACDONALD, Karen
dc.date.accessioned2021-06-10T07:05:18Z
dc.date.available2021-06-10T07:05:18Z
dc.date.issued2019-03-05
dc.identifier.issn1471-2369
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/79016
dc.description.abstractEnBACKGROUND:DOPPS reported that thousands of life-years could be gained in the US and Europe over 5 years by correcting six modifiable haemodialysis practices. We estimated potential life-years gained across 10 European countries using MONITOR-CKD5 study data.METHODS:The DOPPS-based target ranges were used, except for haemoglobin due to label changes, as well as DOPPS-derived relative mortality risks. Percentages of MONITOR-CKD5 patients outside targets were calculated. Consistent with the DOPPS-based analyses, we extrapolated life-years gained for the MONITOR-CKD5 population over 5 years if all patients were within targets.RESULTS:Bringing the 10 MONITOR-CKD5 countries' dialysis populations into compliance on the six practices results in a 5-year gain of 97,428 patient-years. In descending order, survival impact was the highest for albumin levels, followed by phosphate levels, vascular access, haemoglobin, dialysis adequacy, and interdialytic weight gain.CONCLUSIONS:Optimal management of the six modifiable haemodialysis practices may achieve 6.2% increase in 5-year survival.TRIAL REGISTRATION:NCT01121237 . Clinicaltrials.gov registration May 12, 2010 (retrospectively registered).
dc.language.isoen
dc.publisherBioMed Central
dc.subject.enAnaemia
dc.subject.enBiosimilar epoetin alfa
dc.subject.enHaemodialysis
dc.subject.enLife-years
dc.subject.enModifiable haemodialysis practices
dc.title.enPotential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study
dc.typeArticle de revue
dc.identifier.doi10.1186/s12882-019-1251-z
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologie/Urologie et Néphrologie
bordeaux.journalBMC Nephrology
bordeaux.page81
bordeaux.volume20
bordeaux.hal.laboratoriesBioingénierie Tissulaire (BioTis) - U1026*
bordeaux.issue1
bordeaux.institutionCNRS
bordeaux.institutionINSERM
bordeaux.institutionCHU de Bordeaux
bordeaux.institutionInstitut Bergonié
bordeaux.peerReviewedoui
hal.identifierinserm-02081054
hal.version1
hal.origin.linkhttps://hal.archives-ouvertes.fr//inserm-02081054v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMC%20Nephrology&rft.date=2019-03-05&rft.volume=20&rft.issue=1&rft.spage=81&rft.epage=81&rft.eissn=1471-2369&rft.issn=1471-2369&rft.au=COMBE,%20Christian&MANN,%20Johannes&GOLDSMITH,%20David&DELLANNA,%20Frank&ZAOUI,%20Philippe&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée